Enrico Picozza
Partner @ HLM Venture Partners
Boston, United States
Enrico Picozza is a 27-year pioneer in the life sciences with a history of recognizing, developing and commercializing new and disruptive technologies. He is currently a board observer of Tandem Diabetes. He was previously a board observer and special advisor for Interlace Medical, Inc. (sold to Hologic, Inc NASDAQ: HOLX) and board member forSensAble Technologies (sold to GeoMagic). Prior to joining HLM as a Venture Partner, Enrico co-founded HTS Biosystems, Inc., (sold to GEHealthcare Life Sciences/Bicore) an early developer of platforms for drug discovery and point of care diagnostics, where he served as Chief Operating Officer and Chief Technology Officer. Prior to HTS, Enrico held leadership positions with PerkinElmer, Inc. and Applied Biosystems, Inc. While at PerkinElmer, Enrico was one of the founding team members behind the development and commercialization of PCR, the revolutionary DNA-replicating technology that enabled the development of some of the most significant advancements in molecular biology including diagnostics, human ID and personalized medicine. He is the holder of nine patents and has been recognized by the Smithsonian Institute for his achievements in PCR. Enrico is the author of numerous scientific papers and has been a frequent international speaker. In addition he is an advisor to several companies in the field of regenerative medicine and molecular diagnostics. In addition Enrico serves as a member of the BioInspire Council of Advisors for Peoria and a member of Tufts Medical School Invest Council. He earned his master's degree in molecular and cell biology from the University of Connecticut.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Enrico Picozza invests in
Stages Enrico Picozza invests in
Countries Enrico Picozza invests in
Investment Focus
Industry
- SaaS 1 (33%)
- Medical 1 (33%)
- Consumer 1 (33%)
- Software 1 (33%)
- Analytics 1 (33%)
Stage
- Series A 1 (33%)
- Series C 1 (33%)
- Funding Round 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Unified Growth Partners
|
A tech-enabled distribution management organization building robust multi-channel distribution capabilities for the broad retail market with a focus on healthcare products and services.Led by health and financial services industry experts with a comprehensive understanding of the health plan ecosystem including plan design, value-based care,consumerism and distribution. At Unified Growth Partners, we build value for brokers, agents, health plans and most importantly healthcare consumers. Guiding them to make the most appropriate decisions for their families. Medicare, Medicare Advantage, Ancillary, Medicaid, Financial, etc. | $8.6M / Series A / Apr 14, 2025 | |
SensAble Technologies
|
SensAble Technologies, Inc. offers force-feedback haptic devices and touch-enabled 3D modeling software solutions. Its products include FreeForm Modeling Systems, which are 3D touch-enabled systems for medical and dental modeling, product design, digital content creation, and fine arts; and The SensAble Dental Lab System, a digital system forscanning, 3D modeling and design, and 3D fabrication. The company also provides PHANTOM Haptic Devices, which deliver force feedback, 3D navigation, and virtual workspaces; and OpenHaptics, a software development toolkit for developing haptic applications. In addition, it offers 3D touch-enabled modeling systems, software and devices, and 3D modeling software, and sculptural modeling for digital content creation and fine arts. SensAble Technologies serves academic/education, automotive/motorcycle, ceramics, characters and creatures, collectibles/giftware, confectionary, consumer products, dental, engraving, relief and flatware, facial reconstruction, film and video, fine arts and sculpture, footwear, games, home decor and housewares, jewelry, medical, packaging, personal care products, sporting goods, tooling, toys and promotional, assembly path planning, molecular modeling, simulation and visualization, and training industries. The company's products are used in product design, medical and dental modeling, digital content creation, fine arts applications, surgical simulation and stroke rehabilitation, dental restorations, and research and robotic applications. It offers its products through inside sales channels and resellers. The company was founded as SensAble Devices, Inc. in 1993 and changed its name to SensAble Technologies, Inc. in 1996. SensAble Technologies, Inc. is based in Woburn, Massachusetts with a sales office in Tokyo, Japan. | $8M / Mar 08, 2010 | |
Interlace Medical
|
Interlace Medical, Inc. is focused on designing and developing devices for the Interventional Gynecologist to perform office-based procedures to treat diseases and conditions traditionally requiring surgery in the operating room. | $20.5M / Series C / Jul 07, 2009 |
Co-Investors
About HLM Venture Partners
HLM Venture Partners is a proven, successful venture capital health care investor. Over 60 privately held health care companies have benefited from their expertise, resources and commitment. Emerging health care companies can be confident that HLM Venture Partners' longevity, integrity and reputation will be invaluable assets as they worktogether to transform their innovative ideas into market-leading businesses.
HLM Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Chris Nicholson
Entrepreneur in Residence
|
|||
Ed Cahill
Managing Partner
|
|||
|
Enrico Picozza
Partner
|
|||
Mike Wong
Chief Financial Officer
|
|||
Peter Grua
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Enrico Picozza invest in?
Enrico Picozza invests primarily in SaaS, Medical and Consumer startups, most often at Series A and Series C stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Enrico Picozza last invest?
The most recent investment recorded for Enrico Picozza closed in Apr 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
